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Abstract
Background: Niemann-Pick disease (NPD) is a rare autosomal recessive hereditary disease characterized by
deficient activity of acid sphingomyelinase.
Case presentation: We present a case of NPD type B with a unique compound heterozygosity for SMPD1 (NM_
000543.4:c.[84delC];[96G > A]) in which both mutations that induce an early stop codon are located before the
second in-frame initiation codon. The clinical presentation of the patient is compatible with NPD type B. She was
initially diagnosed of Gaucher Disease, but her altered lipid profile led to a clinical suspicion of NPD.
Combined high doses of atorvastatin and ezetimibe were given to treat the severe hypercholesterolemia.
Conclusions: The pharmacological management of the lipid profile in these patients is important. A unique
compound mutation in SMPD1 gene is described.
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Background
Niemann-Pick disease (NPD) is a rare autosomal reces-
sive hereditary disease without gender predilection, with
an estimated frequency of 0.4–1 in 100,000 newborns
[1], characterized by deficient activity of acid sphingo-
myelinase (ASM; E.C. 3.1.4.12). The accumulation of
vacuolated lipid-filled macrophages, known as Niemann-
Pick cells, leads to the involvement of different organs:
liver, spleen, bone marrow, lung and central nervous sys-
tem (CNS) [2].
NPD type A (MIM# 257200) is a neurodegenerative
disorder with massive hepatosplenomegaly and rapidly
progressive neurologic course, leading to death around
the age of three. NPD type B (MIM# 607616) is a non-
neuropathic disorder causing hepatosplenomegaly and
pulmonary involvement. Patients usually reach adult-
hood and their CNS is unaffected. Both types A and B
are caused by mutations in SMPD1 gene, unlike type C,
which is caused by mutations in NPC1 and NPC2 genes.
Diagnosis is performed by bone marrow (BM) biopsies
revealing accumulation of lipid- filled macrophages,
known as sea-blue histiocytes [2], or the demonstration
of low sphingomyelinase activity in an enzyme assay of
cultured skin fibroblasts or isolated leukocytes [1].
ASM or sphingomyelin phosphodiesterase-1 is
encoded by the SMPD1 gene (MIM#607608, GenBank
accession number M81780.1) [3]. More than 140 muta-
tions in NPD have been reported (Human Gene Muta-
tion Database: http://www.hgmd.org). All diagnosed
patients with symptoms and low ASM activity should
get a genetic analysis, as prognosis, and even therapeutic
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management can differ. No specific treatment is cur-
rently available. New therapies, such as olipudase, are
under research [1].
We present a case of NPD type B that has been pre-
viously reported within a series of NPD type A and B
patients [4]. This is a unique case of compound het-
erozygosity in which both mutations induce a prema-
ture stop codon and both are located before the
second in-frame initiation codon that is present in the
SMPD1 gene. New information is added, as the gen-
etic pedigree of her family and her clinical evolution
19 years later are presented. We review its rare genetic
mechanism of action and the very scarce cases of
lipid-lowering management of NPD in the literature.
Case presentation
Our patient, a Caucasian female, was misdiagnosed with
Gaucher disease at the age of two, due to mild hepatos-
plenic enlargement. Both liver and BM biopsies sug-
gested this diagnosis, but these studies were done
elsewhere and results were not available. She underwent
treatment with steroids until the age of 18.
At the age of 36, she presented in Internal Medicine
with a 2-year history of mild dyspnoea. She had previ-
ously been asymptomatic. Physical examination revealed
a wide jaw, significantly closed palpebral fissures, due to
upper palpebral thickening and mildly violaceous colour
over her cheeks and forehead that had increased along
the years (Fig. 1a).
Pulmonary auscultation showed audible pulmonary
crackles. Abdominal examination demonstrated moderate
hepatosplenomegaly. Blood tests showed a normal cell
count, alkaline phosphatase 477 U/L, gamma-glutamyl
transferase 53 U/L, alanine aminotransferase 102 U/L, as-
partate aminotransferase 76 U/L, bilirubin 1mg/dL, total
cholesterol 445mg/dL, triglycerides 287mg/dL and high-
density lipoproteins (HDL) cholesterol 16mg/dL. An ab-
dominal ultrasound disclosed an enlarged liver with hyper
echogenic images compatible with cholesterol deposits. A
liver biopsy done at that age revealed finely vacuolated he-
patocytes and Kupffer cells and slight congestion of the
central vessels, suggestive of a metabolic condition (Fig. 2).
A BM aspirate in the same year showed presence of sea-
blue histiocytes, leading to the suspicion of NPD, along
with the altered lipid profile. An electrocardiogram, a spir-
ometry and an ophthalmologic examination were normal.
A chest X-ray evidenced an interstitial bilateral infiltrate.
At the age of 44, a computerized tomography (CT) (Fig. 3)
revealed a crazy-paving pattern of the lungs, with calcified
granulomas, and hepatic cirrhosis with hypodense nodes
on the left hepatic lobe, signs of portal hypertension and
splenic nodes. At the 36 years old visit, an enzyme assay
measuring ASM activity in leukocytes showed values of
31 nmol/mgmin vs. 692.5 nmol/mgmin in a control,
meaning a 4.5% of activity, establishing the diagnosis of
NPD. The analysis of the SMPD1 gene revealed the pres-
ence of a double heterozygous genetic defect: NM_
000543.4:c.[84delC];[96G > A]. The genetic pedigree of
her family is indicated as follows (Fig. 1b), all of them be-
ing asymptomatic.
The patient continues regular follow-ups and is cur-
rently 55. She leads an active life despite mild dyspnoea.
Fig. 1 a Facial presentation showing a wide jaw, significantly closed palpebral fissure, and mildly violaceous color over the cheeks and forehead.
Taken at the age of 55 years old. b Familial pedigree of the patient: 5429 Father: Nucleotide: NM_000543.4:c.[96G > A];[96=]; Protein:
NP_000534.3:p.[(Trp32Ter)];[Trp32=]; rs3838786: five/six. 5430 Mother: NM_000543.4:c.[84delC];[84=]; NP_000534.3:p.[(Gly29AspfsTer48)];[Gly29=];
rs3838786: six/six. 5431 Index case: NM_000543.4:c.[84delC];[96G > A]; NP_000534.3:p.[(Gly29AspfsTer48)];[(Trp32Ter)]; rs3838786: six/six. 5432 Sister
1: NM_000543.4:c.[84delC];[84=]; NP_000534.3:p.[(Gly29AspfsTer48)];[Gly29=]; rs3838786: five/six. 5433 Sister 2: NM_000543.4:c.[96G > A];[96=];
NP_000534.3:p.[(Trp32Ter)];[Trp32=]; rs3838786: six/six
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She is not receiving any specific treatment for NPD, but
high doses of atorvastatin (80 mg) and ezetimibe have
been administered for the past 10 years, without alter-
ations in transaminases nor muscle aches. Her current
lipid profile values are total cholesterol 174 mg/dL, low-
density lipoproteins (LDL) cholesterol 121 mg/dL, HDL
cholesterol 23 mg/dL and triglycerides 149 mg/dL
(Fig. 4).
Discussion and conclusions
The result of a genetic test showed that our patient was
double heterozygote for SMPD1: NM_000543.4:
c.[84delC];[96G > A]. The C deletion at position 84 of
cDNA promotes a frameshift resulting in an early stop
codon, what presumably generates a null allele [NP_
000534.3:p.(Gly29AspfsTer48)]. This variation was first
described by Sikora et al [5] in 2003 in an double
Fig. 2 Computerized tomography (CT). a. Crazy-paven pattern of the lungs with calcified granulomas. b. Hepatic cirrhosis with hypodense nodes
on the left hepatic lobe, signs of portal hypertension and splenic nodes
Fig. 3 a. Liver biopsy demonstrates enlarged hepatocytes with a finely vacuolated cytoplasm and generalised foamy Kupffer cells filling the
sinusoids (H-E staining x 200). b. Trichrome-stained sections show minimal perisinusoidal fibrosis (x 200). c. Higher magnification shows
cytoplasmic vacuolization in hepatocytes (H), as well as in Kupffer cells (K) (H-E staining x 1000). d. Positive strong reactivity for CD68 highlights
sinusoidal cells
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heterozygote Dutch child, being the second mutated al-
lele NM_000543.4:c.748A > C (NP_000534.3:p.Ser250-
Arg) which causes null enzymatic activity [6]. The child
died at the age of 5 years with a mild NPD type A
phenotype and hepatosplenic enlargement, psychomotor
delay and presence of foam cells in the bone marrow.
The switch of G to A at position 96 of cDNA induces
a premature stop codon before the second in-frame initi-
ation codon (NP_000534.3:p.Trp32Ter). This variation
was first described by Pittis et al [7]. It is the most fre-
quent mutation in Italian NPD type B patients (18.8% of
the alleles). It has been described in 5 Italian patients (1
homozygous patient and 4 heterozygous presenting a
second associated mutation, different from the one har-
boured by our patient). All 5 presented a NPD type B
phenotype without neurological involvement regardless
the associated mutation, with the exception of a 12-year-
old heterozygous girl who developed symptoms during
follow-up. All cases had organomegalies and 2 cases pre-
sented pulmonary involvement. This variation generates
a premature stop codon that presumably would generate
a truncated protein and thus should be considered as a
null allele, expecting a severe phenotype. In fact, the
in vitro functional characterization of the mutation
through the expression of mutant SMPD1 in COS-1
cells confirms this hypothesis as nor the expression of
protein neither residual enzymatic activity were detected
[8]. However, this mutation is associated with a NPD
type B phenotype, and residual enzymatic activity in leu-
kocytes and fibroblasts is detected in patients, achieving
20.9% in the leukocytes of a homozygous patient [7],
which is a high residual enzymatic value for a mutated
protein. The reason of this discrepancy between the
in vitro and the in vivo results is unclear, though may be
related with differences in the post-translational modifi-
cation and subcellular trafficking processes.
The SMPD1 gene has the peculiarity of having two in-
frame initiation ATG codons at positions 1 and 33 and
both can be functional in vitro [9]. Although in vivo
translation of wild type SMPD1 initiates from the first
initiation codon, the second codon can be functional
when the first one has been disabled [7]. To become a
mature and functional enzyme, ASM requires several
post-translational modifications as well as a proper cel-
lular trafficking [10]. In vitro expression of a mutant
ASM lacking the signal peptide results in production of
a non-glycosylated, non-secreted, cytosolic protein that
lacks enzyme activity in cellular extracts [11]. When the
second initiation codon substitutes the first one, the
resulting protein misses 32 N-terminal residues of the
signal peptide (which comprises 46 residues), so this
variant most likely undergoes an abnormal maturing
process. Therefore, the dysfunction is more likely to be
related to gene expression, maturation and intracellular
trafficking than to catalytic activity per se of the enzyme,
as is often the case when pathogenic mutations are
considered.
In our case, both mutations are located before the
second initiation codon and both mutations would result
in a null allele if the second codon were not functional,
as they introduce early stop codons. Although the
underlying mechanism is not fully understood, it is clear
that none of the mutations seem to result in a null allele
and that the second codon is, at least partially, activated
in both alleles. The enzymatic activity of ASM is reduced
enough to generate symptoms, but at the same time is
high enough to be compatible with a NPD type B
phenotype.
Fig. 4 Lipid profile evolution shows a significant reduction of lipid concentrations (almost 70% of total cholesterol and LDL reduction). LDL: low-
density lipoproteins, HDL- high-density lipoproteins, GOT: glutamic oxaloacetic transaminase, GPT: glutamic pyruvic transaminase
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This is a unique case with a compound heterozygosity
with mutations that induce early stop codons and are lo-
cated in the same region before the second initiation
codon, a circumstance that has not been previously re-
ported in the literature.
The correlation between genotype and phenotype in
compound heterozygotes is not evident. Although an
equivalent expression of both alleles should normally be
expected, due to epigenetic factors and methylation con-
ditions, the maternal inherited allele of the SMPD1 gene
may be expressed preferentially [6]. In our case, although
we have the family pedigree, we cannot draw any con-
clusion from this matter since we cannot derive from
our data the contribution of each mutation individually
and theoretically a similar behaviour may be expected.
NPD can pose a diagnostic challenge. Differential diag-
nosis includes Wilson disease, Leigh syndrome, adreno-
leukodystrophy, arginase deficiency and Gaucher disease.
In LAL deficiency, the clinical spectrum can be similar
to NPD, including the lipid profile alteration, but lung
involvement is not commonly reported in LAL defi-
ciency patients [12]. In Gaucher disease, total choles-
terol, as well as LDL and HDL cholesterol are
significantly reduced [13]. The lipid profile of our patient
led to the suspicion that the initial diagnosis of Gaucher
disease was incorrect. However, some authors describe
an association between a low HDL-C level and defects in
the SMPD1 gene causing Type B NPD [14]. The patho-
genesis of the dyslipoproteinemia in these patients is not
yet fully understood.
There are no recommendations for the lipid-lowering
management in NPD. Some authors report that statins
or fibrates may increase transaminases without a sub-
stantial reduction of lipid concentrations in NPD type B
patients [15, 16]. However, there are cases describing an
improvement of lipid profiles and reduction of liver en-
zymes under treatment with fenofibrate [15]. In our
case, our patient received atorvastatin 80 mg and ezeti-
mibe for many years, with a significant reduction of lipid
concentrations (almost 70% of total cholesterol and LDL
reduction) and liver enzymes. Olipudase alfa, a recom-
binant human acid sphingomyelinase (ASM), is used as
an enzyme replacement therapy for the treatment of
non-neurologic manifestations of acid sphingomyelinase
deficiency. A 30-month follow-up clinical trial showed
statistical significant reductions in liver (31%) and spleen
(39%) volumes [17]. There was a mean increase in lung
diffusing capacity of 35%, and clinically relevant im-
provements in infiltrative lung disease parameters, and
lipid profiles improved in all 5 patients. Improvements
in bone mineral density of the spine were observed in
some patients. Lyso-sphingomyelin in dried blood spots
decreased with olipudase alfa treatment [17]. We offered
our patient to be treated with olipudase alfa, sending her
to another hospital to be included in a clinical trial, but
she repeatedly refused.
In conclusion, we present a case of NPD type B with a
unique genetic mechanism: a compound heterozygosity
of mutations that induce a premature stop codon located
before the second initiation codon, circumstance that
has not been reported in the literature. We also discuss
the pharmacological management of the lipid profile,
showing that, in our patient, a combination of a high in-
tensity statin with ezetimibe was useful, although more
research is needed to broaden the available evidence on
this topic.
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